VALBIOTIS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.94 EUR | +1.03% |
|
+1.68% | -21.20% |
| 26/04 | Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03/04 | Valbiotis: launch of Valbiotis PRO Cholesterol in May | CF |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -21.20% | 65.67M | - | ||
| -2.61% | 103B | B+ | ||
| +1.95% | 95.28B | B+ | ||
| +1.46% | 22.15B | B | ||
| -15.87% | 21.02B | B+ | ||
| -8.58% | 18.15B | A- | ||
| -38.74% | 16.73B | A- | ||
| -13.26% | 16.05B | B | ||
| +4.66% | 13.68B | C+ | ||
| +35.37% | 12.17B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ALVAL Stock
- Ratings VALBIOTIS
